ASCO 2019

General views of the 55th Annual Meeting of the American Association of Clinical Oncology (ASCO) - held in the McCormick Place in Chicago, Ill. Courtesy: 2019 © ASCO/Luke Franke 2019.

RC48-ADC Shows Clinically Meaningful Results in Advanced HER2+ Urothelial Cancer

Results from a Phase II Clinical Trial of RC48-ADC (NCT03507166), an antibody-drug conjugate or ADC being developed by Chinese biotech RemeGen, show clinically meaningful topline results. The trial data were presented during the annual meeting of the American Society of Clinical Oncology (ASCO), being held May...

Eric Rosenthal Reports